Conjugation is the heart of Antibody-Drug Conjugate (ADC) technology. Where biology meets chemistry. At Aurigene, we offer state-of-the-art conjugation services that ensure precise, stable, and reproducible attachment of payloads to antibodies. Our deep understanding of bioconjugation science, coupled with advanced analytics, allows us to optimize every step, from site selection to linker-payload attachment. Enabling the creation of ADCs with optimal Drug-to-Antibody Ratios (DAR), stability, and therapeutic activity. Whether your goal is preclinical proof-of-concept or gram scale batches, we tailor conjugation strategies to your molecule’s biology, mechanism of action, and intended indication.
Thiol-Maleimide Conjugation
- Standard approach using reduced interchain cysteines
- Controlled DAR (typically 2, 4, or 8)
- Efficient and scalable
Ideal for fast turnaround and widely accepted in early-phase ADC development
Lysine Conjugation
- Non-specific conjugation to surface-exposed lysines
- Produces heterogeneous ADCs
Suitable for early-stage screening and rapid evaluation of new payloads or linkers
Enzymatic Conjugation
- Site-specific conjugation via transglutaminase, sortase, or glycoengineering
- High positional control and consistency
Best for developing next-gen, highly homogeneous ADCs
Branched and Dual Payload Conjugation
- Technologies to enable two different payloads on the same antibody
- Balanced DAR per payload
Designed to overcome tumor heterogeneity or resistance mechanisms
Site-Specific Technologies (Engineered Cysteines)
- Controlled site insertion for cleaner ADCs
Ensures uniform DAR and improved pharmacokinetics
Why choose Aurigene?
At Aurigene, conjugation isn’t just a chemical reaction, it’s a scientifically guided process. We bring over a decade of experience in designing and optimizing conjugation strategies across diverse payloads, linkers, and antibody formats, including bispecifics and Fab fragments. Our conjugation team works hand-in-hand with our analytical, purification, and in vitro biology teams to ensure each ADC meets stringent quality, reproducibility, and performance benchmarks.
We provide:
Expert design of DAR optimization and conjugation strategy
Multiple conjugation formats tailored to indication and payload class
Capability to support cleavable and non-cleavable linkers
Advanced purification to isolate mono-, di-, or specific DAR species
Fully integrated analytics including LC-MS, HIC, SEC, UV-Vis, and endotoxin testing
Seamless transition to in vitro assays, stability studies, and in vivo efficacy models
Whether you are screening novel linker-payloads or developing a clinical candidate, Aurigene ensures your conjugation step is robust, reproducible, and ready for scale-up.
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Connect with our scientific experts for your drug discovery, development, and manufacturing needs
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
Learning Resources
Oligonucleotide as a novel class of therapeutic modality
Oligonucleotides as a therapeutic class is a revolutionary approach to discover new and important therapeutic agents for treating human diseases. RNA-based intervention at times works in cases where other modalities do not work. For example, it may help in treating inborn errors in metabolism, genetic disorders and rareOligonucleotide therapeutics is the use of c...
Read More
HPAPI Molecule from Development to Market
The global Highly Potent Active Pharmaceutical Ingredients (HPAPI) market is expected to reach USD 26.84 Billion by 2023 from USD 17.72 Billion in 2018, at a CAGR 8.7%....
Read More
Systematic formulation design - shorten development cost & time
Project Challenge: Existing formulation (lower strength - 50 mg) was manufactured using direct compression process. This formulation posed poor powder flow and content uniformity issues during scale-up. Development of new strength 150 mg without any process issues was a challenge. Solution design: Preliminary pre-formulation, stress study and PSD impact assessmen...
Read More
An efficient and convenient protocol for the synthesis of tetracyclic isoindolo[1,2-a]quinazoline derivatives
2016
A convenient and one-pot synthesis of tetracyclic isoindolo [1,2-a]quinazoline derivatives via Lewis acid mediated sequential C–N bond formation reactions is reported. This protocol provides a simple and rapid strategy for the synthesis of 12-benzylidene-10,12-dihydroisoindolo[1,2-b]quinazoline derivatives. However, a variety of tetracyclo indole fused quinazol...
Read More-
Development and assessment of a Bcs class II - SGLT2 (Sodium Glucose Cotransporter 2) inhibitor drug in the form of solid lipid Nanoparticles by selecting different lipids, co-surfactants, and manufacturing techniques
Drug Delivery System (DDS) has been used successfully in the past few decades to cure illnesses and enhance health because of its improved systemic circulation and ability to regulate the drug's pharmacological action. As pharmacology and pharmacokinetics advanced, the idea of controlled release emerged, demonstrating the significance of drug release in assessing...
Read More -
Development of novel paullone-based PROTACs as anticancer agents
Proteolysis-targeting chimera (PROTACs) represents a promising modality that has gained significant attention for cancer treatment. Using PROTAC technology, we synthesized novel structurally modified paullone-based PROTACs using Cereblon (CRBN) and Von Hippel–Lindau (VHL) E3 ligands....
Read More -
Development and verification of RP-HPLC method for the quantitative determination of Decitabine in tablet dosage formulation
Decitabine is an anti-cancer chemotherapy drug. This article describes method development and method verification of Assay of Decitabine in tablet formulation. A new, precise, rapid, accurate RP-HPLC method has been developed for the estimation of Decitabine in pharmaceutical tablets dosage form. After optimization the good chromatographic separation was achieved...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market